Sacituzumab Govitecan in Heavily Pretreated Metastatic Triple-Negative Breast Cancer: A Step in the Right Direction


Get Permission


“Trop-2 is a novel therapeutic target, suitable for antibody-drug conjugate development.”
— Francisco J. Esteva, MD, PhD

Tweet this quote

IN A SINGLE-ARM multicenter trial reported by Bardia and colleagues1 and reviewed in this issue of The ASCO Post, the use of sacituzumab govitecan (IMMU-132) showed a response rate of 30% and a clinical benefit rate of 46% in heavily pretreated patients with metastatic triple-negative breast cancer. The median progression-free survival was 6 months, and the median overall survival was 16 months. These data are promising because objective responses and prolonged disease stabilization are infrequent in patients with refractory or relapsed metastatic triple-negative breast cancer. 

Different Molecular Subtypes 

ADVANCED TRIPLE-NEGATIVE breast cancers are highly aggressive tumors that progress through conventional cytotoxic chemotherapies, used either in combination or sequentially as single agents. Triple-negative breast cancer is a heterogeneous disease that includes a diversity of tumors driven by different molecular pathways or genetic alterations. 

Approximately 15% of triple-negative breast cancers carry BRCA mutations, which make them more sensitive to platinum salts and potentially poly (ADP-ribose) polymerase (PARP) inhibitors. The majority of triple-negative breast cancers harbor p53 mutations, which are not “druggable” with available technology. Microarray studies identified six different molecular subtypes within the triple-negative breast cancer group. A subset of patients with triple-negative breast cancer respond to PD-1/PD-L1 checkpoint blockade, which remains an area of active investigation. 

Dr. Esteva is Professor of Medicine; Director, Breast Medical Oncology Program; Associate Director of Clinical Investigation, Laura & Isaac Perlmutter Cancer Center, New York University Langone Medical Center.

Novel Therapeutic Target 

TROP-2 is a glycoprotein that is overexpressed in triple-negative breast cancer and other epithelial malignancies. Trop-2 overexpression correlates with a poor prognosis in breast cancer and other solid tumors. The study by Bardia and colleagues showed that Trop-2 is a novel therapeutic target, suitable for antibody-drug conjugate development. Sacituzumab govitecan is an antibody directed against Trop-2 bound to SN-38, a potent chemotherapeutic drug. 

Developing targeted chemotherapy using an antibody-drug conjugate approach in triple-negative breast cancer is a step in the right direction. If larger studies confirm the efficacy and safety reported in this early-phase trial, sacituzumab govitecan would represent a major improvement in the treatment of advanced triple-negative breast cancer. Furthermore, this study reflects the importance of target validation and rational drug development, especially in a subtype of breast cancer characterized by a lack of validated therapeutic targets. 

DISCLOSURE: Dr. Esteva reported no conflicts of interest. 

REFERENCE 

1. Bardia A, et al: Efficacy and safety of anti-Trop-2 antibody drug conjugate sacituzumab govitecan (IMMU-132) in heavily pretreated patients with metastatic triple-negative breast cancer. J Clin Oncol 35:2141-2148, 2017.


Related Articles

Anti–Trop-2 Antibody-Drug Conjugate Produces Durable Responses in Metastatic Triple-Negative Breast Cancer


“Sacituzumab govitecan induced early and durable responses in heavily pretreated patients with metastatic triple-negative breast cancer.”
— Aditya Bardia, MD, MPH, and colleagues

Tweet this quote

AS REPORTED in the Journal of Clinical Oncology by Aditya Bardia, MD,...

Advertisement

Advertisement



;
Advertisement

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.